The PFS gain is consistent with the Okayama Lung Cancer Study Group Trial 1001 in Japanese patients with previously untreated EGFR-mutated advanced NSCLC,29 showing that bevacizumab added to gefitinib extended PFS by 4–5 months over historical controls receiving gefitinib monotherapy.5,30 This benefit in PFS is also similar to the ARTEMIS-CTONG1509 study31 showing a significant reduction in the risk of progression with bevacizumab added to erlotinib versus erlotinib alone (HR = 0.55; 95% CI, 0.41–0.73). The gene discussed is EGFR; the disease is lung cancer.